Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07519772 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
NCT07519772: Recruiting Phase 1 study, sponsored by Merck Sharp & Dohme.
NCT07519772 is a Phase 1 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 200 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (233% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07519772, a Phase 1 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
Study Summary
Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system. In this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer. The goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.
Primary Outcome
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Interventions
- BIOLOGICAL MK-1045
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-05-03 |
| Est. Completion | 2031-04-01 |
| Phase | Phase 1 |
What NCT07519772 shows while recruiting
NCT07519772 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (233% higher).
The record links to 0 conditions, and to 1 intervention - of which MK-1045 is the first listed.
NCT07519772 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07519772 about?
NCT07519772 is a clinical study titled "A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)". Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph node...
What is the current status of trial NCT07519772?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2026-05-03. Estimated completion is 2031-04-01.
What interventions are being tested in trial NCT07519772?
The interventions under investigation include: MK-1045 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07519772?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07519772's enrollment target sits among peer trials
200 259th of 2000 higher than 1,724 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI